CORONAVIRUS
Chiesi Group is closely monitoring the COVID-19 outbreak and is acting in order to make the health and wellbeing of patients and employees a priority. Dedicated teams across our network are taking measures to protect the continuous supply of our medicines in all countries and implemented strict guidelines to ensure the safety of all employees across the Chiesi Group in line with government policies and needs and following the WHO recommendations. We are committed to our focus on improving the quality of human life and put people at the center of our actions, to protect the health and wellbeing of our employees, patients and partners.
23
09/25
NEWS
Chiesi Announces Results of the Tanimilast Phase III...
Chiesi Group today announced the results of the tanimilast Phase III PILASTER clinical study in Chronic...
  • PRESS RELEASE
    Chiesi Completes Clinical Development Program for...
    Key highlights: Successfully completed the TRECOS Phase III study*, supporting the long-term safety of Chiesi’s carbon...
© 2025 CHIESI Farmaceutici S.p.A.
VAT IT 01513360345
Company's Capital: Euro 75.000.000
Companies Register Office - Parma N.15739
REA: 159271

PHARMACOVIGILANCE

TO REPORT ADVERSE DRUG EVENTS/REACTIONS PLEASE CLICK HERE


follow us on: